FORSYTHE, Nicholas, Alaa REFAAT, Arman JAVADI, Hajrah KHAWAJA, Jessica-Anne WEIR, Heba EMAM, Wendy L. ALLEN, Frank BURKAMP, Vlad POPOVICI, Puthen V. JITHESH, Claudio ISELLA, Melissa J. LABONTE, Ian G. MILLS, Patrick G. JOHNSTON and Sandra VAN SCHAEYBROECK. The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer. Molecular Cancer Therapeutics. PHILADELPHIA: American Association for Cancer Research, 2018, vol. 17, No 6, p. 1280-1290. ISSN 1535-7163. Available from: https://dx.doi.org/10.1158/1535-7163.MCT-17-0603.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer
Authors FORSYTHE, Nicholas (826 United Kingdom of Great Britain and Northern Ireland), Alaa REFAAT (826 United Kingdom of Great Britain and Northern Ireland), Arman JAVADI (826 United Kingdom of Great Britain and Northern Ireland), Hajrah KHAWAJA (826 United Kingdom of Great Britain and Northern Ireland), Jessica-Anne WEIR (826 United Kingdom of Great Britain and Northern Ireland), Heba EMAM (826 United Kingdom of Great Britain and Northern Ireland), Wendy L. ALLEN (826 United Kingdom of Great Britain and Northern Ireland), Frank BURKAMP (826 United Kingdom of Great Britain and Northern Ireland), Vlad POPOVICI (642 Romania, guarantor, belonging to the institution), Puthen V. JITHESH (634 Qatar), Claudio ISELLA (380 Italy), Melissa J. LABONTE (826 United Kingdom of Great Britain and Northern Ireland), Ian G. MILLS (826 United Kingdom of Great Britain and Northern Ireland), Patrick G. JOHNSTON (826 United Kingdom of Great Britain and Northern Ireland) and Sandra VAN SCHAEYBROECK (826 United Kingdom of Great Britain and Northern Ireland).
Edition Molecular Cancer Therapeutics, PHILADELPHIA, American Association for Cancer Research, 2018, 1535-7163.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.856
RIV identification code RIV/00216224:14310/18:00105592
Organization unit Faculty of Science
Doi http://dx.doi.org/10.1158/1535-7163.MCT-17-0603
UT WoS 000433932800014
Keywords in English ENDOPLASMIC-RETICULUM STRESS; SELECTIVE HDAC6 INHIBITOR; MULTIPLE-MYELOMA; ER STRESS; PROTEASOME INHIBITORS; AGGRESOME FORMATION; INDUCED APOPTOSIS; COLON-CANCER; CELL-DEATH; PATHWAY
Tags International impact, Reviewed
Changed by Changed by: Mgr. Michaela Hylsová, Ph.D., učo 211937. Changed: 16/1/2019 21:42.
Abstract
BRAF(V600E) mutations occur in similar to 10% of colorectal cancer cases, are associated with poor survival, and have limited responses to BRAF/MEK inhibition with or without EGFR inhibition. There is an unmet need to understand the biology of poor prognostic BRAFMT colorectal cancer. We have used differential gene expression and pathway analyses of untreated stage II and stage III BRAFMT (discovery set: n = 31; validation set: n = 26) colorectal cancer, and an siRNA screen to characterize the biology underpinning the BRAFMT subgroup with poorest outcome. These analyses identified the unfolded protein response (UPR) as a novel and druggable pathway associated with the BRAFMT colorectal cancer subgroup with poorest outcome. We also found that oncogenic BRAF drives endoplasmic reticulum (ER) stress and UPR pathway activation through MEK/ERK. Furthermore, inhibition of GRP78, the master regulator of the UPR, using siRNA or small molecule inhibition, resulted in acute ER stress and apoptosis, in particular in BRAFMT colorectal cancer cells. In addition, dual targeting of protein degradation using combined Carfilzomib (proteasome inhibitor) and ACY-1215 (HDAC6-selective inhibitor) treatment resulted in marked accumulation of protein aggregates, acute ER stress, apoptosis, and therapeutic efficacy in BRAFMT in vitro and xenograft models. Mechanistically, we found that the apoptosis following combined Carfilzomib/ACY-1215 treatment is mediated through increasedCHOPexpression. Taken together, our findings indicate that oncogenic BRAF induces chronic ER stress and that inducers of acute ER stress could be a novel treatment strategy for poor prognostic BRAFMT colorectal cancer.
PrintDisplayed: 21/7/2024 00:17